Literature DB >> 18241917

Oscillatory membrane currents paradoxically induced via NO-activated pathways in detrusor cells.

Shunichi Kajioka1, Shinsuke Nakayama, Narihito Seki, Seiji Naito, Alison F Brading.   

Abstract

Oscillatory inward membrane currents (I(oscil-in)) reflecting intracellular Ca(2+) ([Ca(2+)](i)) activity in detrusor cells, are thought to play an important role in producing tonic bladder contractions during micturition. The present patch clamp study revealed a new activation mechanism: sodium nitroprusside (SNP), a nitric oxide (NO) donor induced I(oscil-in) in a subpopulation of detrusor cells. The inhibitory effect of niflumic acid on SNP-induced I(oscil-in) suggests that Ca(2+)-activated Cl(-) channels are responsible for this current. In addition, SNP-induced I(oscil-in) required the cooperation of Ca(2+) influx through SK&F96365-sensitive channels and intracellular Ca(2+) release channels sensitive to ryanodine but insensitive to xestospongin C (XeC). This is also true for muscarinic agonist (carbachol: CCh)-induced I(oscil-in). However, 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a guanylyl cyclase inhibitor, suppressed SNP-induced I(oscil-in) but not CCh-induced I(oscil-in). The results suggest that a subpopulation of detrusor cells employ the NO/cGMP cascade to potentiate bladder contraction. Mechanisms underlying NO-induced I(oscil-in) are likely to contribute not only to the physiology but also to the pathophysiology of the lower urinary tract.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18241917     DOI: 10.1016/j.ceca.2007.11.008

Source DB:  PubMed          Journal:  Cell Calcium        ISSN: 0143-4160            Impact factor:   6.817


  4 in total

1.  Nitric oxide-induced biphasic mechanism of vascular relaxation via dephosphorylation of CPI-17 and MYPT1.

Authors:  Toshio Kitazawa; Shingo Semba; Yang Hoon Huh; Kazuyo Kitazawa; Masumi Eto
Journal:  J Physiol       Date:  2009-05-26       Impact factor: 5.182

Review 2.  Systematic review and meta-analysis on phosphodiesterase 5 inhibitors and α-adrenoceptor antagonists used alone or combined for treatment of LUTS due to BPH.

Authors:  Xing-Huan Wang; Xiao Wang; Ming-Jun Shi; Sheng Li; Tao Liu; Xin-Hua Zhang
Journal:  Asian J Androl       Date:  2015 Nov-Dec       Impact factor: 3.285

Review 3.  Clinical and preclinical treatment of urologic diseases with phosphodiesterase isoenzymes 5 inhibitors: an update.

Authors:  Wen-Hao Zhang; Xin-Hua Zhang
Journal:  Asian J Androl       Date:  2016 Sep-Oct       Impact factor: 3.285

4.  Comparative effectiveness of oral drug therapies for lower urinary tract symptoms due to benign prostatic hyperplasia: a systematic review and network meta-analysis.

Authors:  Xinghuan Wang; Xiao Wang; Sheng Li; Zhe Meng; Tao Liu; Xinhua Zhang
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.